Table 3.

The percentage of TLR9-positive PBMCs, lymphocytes B CD19⁺, and lymphocytes T CD3⁺ in relation to SLICC/ACR organ damage.

Cells subpopulations (% positive cells)	SLICC = 0  n = 13  (a)	SLICC = 1  n = 14  (b)	SLICC = 2  n = 5  (c)	Healthy  n = 15  (d)	Statistical significance
TLR9 in PBMC
$\stackrel{-}{x}\pm \text{SD}$	31.04 ± 31.93	35.02 ± 33.89	58.79 ± 27.01	1.09 ± 0.75	(a)–(d) P < 0.003
Median	13.92	27.30	64.40	1.10	(b)–(d) P < 0.001
Range	(0.72–97.5)	(0.3–98.37)	(27.75–93.53)	(0.05–2.50)	(c)-(d) P < 0.001
TLR9 in CD3
$\stackrel{-}{x}\pm \text{SD}$	14.47 ± 21.71	22.88 ± 32.12	28.81 ± 26.21	3.14 ± 7.85
Median	4.26	1.98	23.58	0.75
Range	(0.36–66.9)	(0.4–80.44)	(5.37–62.73)	(0.00–30.18)
TLR9 in CD19
$\stackrel{-}{x}\pm \text{SD}$	2.69 ± 2.19	6.04 ± 7.59	9.95 ± 7.62	0.78 ± 0.95	(c)-(d) P < 0.006
Median	3.25	3.02	10.29	0.45
Range	(0.1–6.52)	(0.10–26.00)	(3.32–22.0)	(0.00–3.00)

$\stackrel{-}{x}$: mean; SD: standard deviation.

The bold font emphasises that the higher SLICC value is parallelled with the higher percentage of PBMCs, lymphocytes CD3+ and CD19+ with TLR9.